Samsung Bioepis Co. Ltd.

Form 483 issued November 22, 2024 · Incheon, South Korea

Inspection
Nov 20 – Nov 22, 2024
Observations
2
Pages
4
FEI number
3010031951

In short: On November 22, 2024, FDA issued a Form 483 with 2 observations to Samsung Bioepis Co. Ltd. in Incheon, South Korea (FEI 3010031951) after an inspection that ran Nov 20 – Nov 22, 2024. The investigator was Rajiv R. Srivastava. Most observations concern quality system; the most-cited regulation is 21 CFR 211.198 (complaint files).

At a glance

2 of 2 observations on this 483 concern quality system.

Quality system2

Most cited: 21 CFR 211.198 (1×) · 211.22 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Procedures describing the handling of written and oral complaints related to dtu g products are…

  2. 02

    Responsibilities and procedures for quality units are not in writing and/or followed to ensure a need…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Samsung Bioepis Co. Ltd.?

FDA listed 2 observations on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.198 (complaint files). The opening words of each observation are shown on this page.

Who inspected Samsung Bioepis Co. Ltd.?

Rajiv R. Srivastava is named on this Form 483, for the inspection of Nov 20 – Nov 22, 2024. Each investigator has a profile showing what they cite most.

When was Samsung Bioepis Co. Ltd. inspected by FDA?

The inspection ran Nov 20 – Nov 22, 2024, and the Form 483 is dated November 22, 2024.

How do I get the full Form 483 for Samsung Bioepis Co. Ltd.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free